Celcuity Inc.

CELC Nasdaq CIK: 0001603454

Company Information

Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 16305 36TH AVENUE N, MINNEAPOLIS, MN, 55446
Mailing Address 16305 36TH AVENUE N, MINNEAPOLIS, MN, 55446
Phone 763-392-0767
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$165.70M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 26, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 24, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 9, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
3 Initial insider ownership report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 12, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • FDA granted Priority Review for lead drug candidate gedatolisib with a decision date of July 17, 2026.
  • Positive progression-free survival results achieved in the VIKTORIA-1 clinical trial.
View Analysis

Insider Trading

STRONG SELL 2 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 8071)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.